Description

• General description: This orthogonally-protected diaminopropionic acid derivative is based on the hindered Dde variant ivDde. The side-chain ivDde group is considerably more stable to piperidine than Dde and is less prone to migrate from protected to unprotected side-chains [1]. However, migration from side-chain to the unprotected α-amino group of Dpr is unavoidable [2]. This side-reaction can, however, be minimized by the appropriate choice of coupling method for the subsequent residue, see [3].When removing ivDde in the presence of allyl-based protecting groups, allyl alcohol should be included in the deprotection solution to prevent reduction of the allyl group [4]. Associated Protocols and Technical ArticlesCleavage and Deprotection Protocols for Fmoc SPPSLiterature references[1] S. R. Chhabra, et al. (1998) Tetrahedron Lett., 39, 1603. [2] R. Wilhelm, et al., Poster 34 presented at the 16th American Peptide Symposium, Minneapolis, 1999. [3] J. Beythien & P. Schneeberger, in ′Peptides 2000, Proc. 26th European Peptide Symposium′, EDK, Paris, 2001, pp. 361. [4] B. Rohwedder, et al. (1998) Tetrahedron Lett., 39, 1175.
• Linkage: Replaces: 04-12-1195
• Analysis Note: Color (visual): white to slight yellow to beigeAppearance of substance (visual): powderIdentity (IR): passes testEnantiomeric purity: ≥ 99.5 % (a/a)Purity (TLC(157A)): ≥ 98 %Purity (TLC(CMA2)): ≥ 98 %Assay (HPLC, area%): ≥ 99.0 % (a/a)Solubility (1 mmole in 2 ml DMF): clearly solubleAssay (acidimetric): ≥ 95.0 %Water (K. F.): ≤ 1.00 %To see the solvent systems used for TLC of Novabiochem® products please click here.
• Legal Information: Novabiochem is a registered trademark of Merck KGaA, Darmstadt, Germany